ALK and non-small cell lung carcinoma: In analogy to combined EGFR-inhibition (cetuximab) and radiotherapy in HNSCC, it is conceivable that ALK-inhibition may provide a less toxic alternative to chemotherapy for concurrent treatment of ALK-positive NSCLC with radiotherapy [41].